Một chiến lược phân tích mới để tích hợp dữ liệu mety hóa và biểu hiện tiết lộ các con đường cốt lõi liên quan đến nguyên nhân bệnh lý ung thư tuyến giáp

Xing M: Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer. 2013, 13 (3): 184-199. Cohen Y, Xing M, Mambo E, Guo Z, Wu G, Trink B, et al: BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst. 2003, 95 (8): 625-627. Kikuchi Y, Tsuji E, Yagi K, Matsusaka K, Tsuji S, Kurebayashi J, et al: Aberrantly methylated genes in human papillary thyroid cancer and their association with BRAF/RAS mutation. Front Genet. 2013, 4: 271- Knauf JA, Fagin JA: Role of MAPK pathway oncoproteins in thyroid cancer pathogenesis and as drug targets. Curr Opin Cell Biol. 2009, 21 (2): 296-303. Mitsutake N, Miyagashi M, Mitsutake S, Akeno N, Mesa C, Knauf JA: BRAF mediates RET/PTC-induced mitogen-activated protein kinase activation in thyroid cells: functional support for requirement of the RET/PTC-RAS-BRAF pathway in papillary thyroid carcinogenesis. Endocrinology. 2006, 147 (2): 1014-1019. Cancer Genome Atlas Research Network: Integrated genomic characterization of papillary thyroid carcinoma. Cell. 2014, 159 (3): 676-690. Mohammadi-asl J, Larijani B, Khorgami Z, Tavangar SM, Haghpanah V, Kheirollahi M, et al: Qualitative and quantitative promoter hypermethylation patterns of the P16, TSHR, RASSF1A and RARbeta2 genes in papillary thyroid carcinoma. Med Oncol. 2011, 28 (4): 1123-1128. Hoque MO, E, WH, M, P, MA, et al: Quantitative assessment of promoter methylation profiles in thyroid neoplasms. J Clin Endocrinol Metab. 2005, 90 (7): 4011-4018. Xing M, Cohen Y, Mambo E, Tallini G, Udelsman R, Ladenson PW: Early occurrence of RASSF1A hypermethylation and its mutual exclusion with BRAF mutation in thyroid tumorigenesis. Cancer Res. 2004, 64 (5): 1664-1668. Rodriguez-Rodero S, Fernandez AF, Fernandez-Morera JL, Castro-Santos P, Bayon GF, Ferrero C, et al: DNA methylation signatures identify biologically distinct thyroid cancer subtypes. J Clin Endocrinol Metab. 2013, 98 (7): 2811-2821. Cakir M, Grossman AB: Medullary thyroid cancer: molecular biology and novel molecular therapies. Neuroendocrinology. 2009, 90 (4): 323-348. Lu'o'ng KV, Nguyen LT: The role of thiamine in cancer: possible genetic and cellular signaling mechanisms. Cancer Genomics Proteomics. 2013, 10 (4): 169-185. Pisarev MA, Thomasz L, Juvenal GJ: Role of transforming growth factor beta in the regulation of thyroid function and growth. Thyroid. 2009, 19 (8): 881-892. Vieira JM, Santos SC, Espandinha C, Correia I, Vag T, Casalou C, et al: Expression of vascular endothelial growth factor (VEGF) and its receptors in thyroid carcinomas of follicular origin: a potential autocrine loop. Eur J Endocrinol. 2005, 153 (5): 701-709. McGregor LM, McCune BK, Graff JR, McDowell PR, Romans KE, Yancopoulos GD, et al: Roles of trk family neurotrophin receptors in medullary thyroid carcinoma development and progression. Proc Natl Acad Sci U S A. 1999, 96 (8): 4540-4545. Owens LV, Xu L, Dent GA, Yang X, Sturge GC, Craven RJ, et al: Focal adhesion kinase as a marker of invasive potential in differentiated human thyroid cancer. Ann Surg Oncol. 1996, 3 (1): 100-105. Yeh MW, Rougier JP, Park JW, Duh QY, Wong M, Werb Z, et al: Differentiated thyroid cancer cell invasion is regulated through epidermal growth factor receptor-dependent activation of matrix metalloproteinase (MMP)-2/gelatinase A. Endocr Relat Cancer. 2006, 13 (4): 1173-1183. Sastre-Perona A, Santisteban P: Role of the wnt pathway in thyroid cancer. Front Endocrinol (Lausanne). 2012, 3: 31- Malaguarnera R, Vella V, Vigneri R, Frasca F: p53 family proteins in thyroid cancer. Endocr Relat Cancer. 2007, 14 (1): 43-60. Yamashita AS, Geraldo MV, Fuziwara CS, Kulcsar MAV, Friguglietti CU, da Costa RB, et al: Notch pathway is activated by MAPK signaling and influences papillary thyroid cancer proliferation. Transl Oncol. 2013, 6 (2): 197-205. Huang WY, Hsu SD, Huang HY, Sun YM, Chou CH, Weng SL, et al: MethHC: a database of DNA methylation and gene expression in human cancer. Nucleic Acids Res. 2014, 43 (D1): D856-D861. Lowe SW, Lin AW: Apoptosis in cancer. Carcinogenesis. 2000, 21 (3): 485-495. Shih A, Davis FB, Lin HY, Davies PJ: Resveratrol induces apoptosis in thyroid cancer cell lines via a MAPK- and p53-dependent mechanism. J Clin Endocrinol Metab. 2002, 87 (3): 1223-1232. Jones PA, Baylin SB: The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002, 3 (6): 415-428. Baylin SB, Ohm JE: Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction?. Nat Rev Cancer. 2006, 6 (2): 107-116. Feinberg AP, Oshimura M, Barrett JC: Epigenetic mechanisms in human disease. Cancer Res. 2002, 62 (22): 6784-6787. Alashwal H, Dosunmu R, Zawia NH: Integration of genome-wide expression and methylation data: relevance to aging and Alzheimer's disease. Neurotoxicology. 2012, 33 (6): 1450-1453. Gervin K, Vigeland MD, Mattingsdal M, Hammero M, Nygard H, Olsen AO, et al: DNA methylation and gene expression changes in monozygotic twins discordant for psoriasis: identification of epigenetically dysregulated genes. PLoS Genet. 2012, 8 (1): e1002454- Paziewska A, Dabrowska M, Gorya K, Antoniewicz A, Dobruch J, Mikula M, et al: DNA methylation status is more reliable than gene expression at detecting cancer in prostate biopsy. Br J Cancer. 2014, 111 (4): 781-789. Fan S, Zhang X: CpG island methylation pattern in different human tissues and its correlation with gene expression. Biochem Biophys Res Commun. 2009, 383 (4): 421-425. Li M, Balch C, Montgomery JS, Jeong M, Chung JH, Yan P, et al: Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer. BMC Med Genomics. 2009, 2: 34- Taskesen E, Havermans M, van Lom K, Sanders MA, van Norden Y, Bindels E, et al: Two splice-factor mutant leukemia subgroups uncovered at the boundaries of MDS and AML using combined gene expression and DNA-methylation profiling. Blood. 2014, 123 (21): 3327-3335. Kim D, Shin H, Song YS, Kim JH: Synergistic effect of different levels of genomic data for cancer clinical outcome prediction. J Biomed Inform. 2012, 45 (6): 1191-1198. List M, Hauschild AC, Tan Q, Kruse TA, Mollenhauer J, Baumbach J, et al: Classification of breast cancer subtypes by combining gene expression and DNA methylation data. J Integr Bioinform. 2014, 11 (2): 236- Remenyi A, Scholer HR, Wilmanns M: Combinatorial control of gene expression. Nat Struct Mol Biol. 2004, 11 (9): 812-815. Bird AP: DNA methylation versus gene expression. J Embryol Exp Morphol. 1984, 83 Suppl: 31-40. Sherr CJ: Cell cycle control and cancer. Harvey Lect. 2000, 96: 73-92. Butcher LM, Beck S: Probe Lasso: a novel method to rope in differentially methylated regions with 450K DNA methylation data. Methods. 2015, 72: 21-28. Du P, Zhang X, Huang CC, Jafari N, Kibbe WA, Hou L, et al: Comparison of Beta-value and M-value methods for quantifying methylation levels by microarray analysis. BMC Bioinformatics. 2010, 11: 587- Teschendorff AE, Marabita F, Lechner M, Bartlett T, Tegner H, Gomez-Cabrero D, et al: A beta-mixture quantile normalization method for correcting probe design bias in Illumina Infinium 450 k DNA methylation data. Bioinformatics. 2013, 29 (2): 189-196. Johnson WE, Li C, Rabinovic A: Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics. 2007, 8 (1): 118-127. Benjamini YHY, Hochberg Y: Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of Royal Statistical Society B. 1995, 57 (1): 289-300. Robinson MD, McCarthy DJ, Smyth GK: edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010, 26 (1): 139-140. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, et al: Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004, 5 (10): R80- Schroder MS, Culhane AC, Quackenbush J, Haibe-Kains B: survcomp: an R/Bioconductor package for performance assessment and comparison of survival models. Bioinformatics. 2011, 27 (22): 3206-3208. R Development Core Team: R: A language and environment for statistical computing. R Foundation for Statistical Computing: Vienna, Austria. 2014 Zaykin DV: Optimally weighted Z-test is a powerful method for combining probabilities in meta-analysis. J Evol Biol. 2011, 24 (8): 1836-1841. Bakir-Gungor B, Egemen E, Sezerman OU: PANOGA: a web server for identification of SNP-targeted pathways from genome-wide association study data. Bioinformatics. 2014, 30 (9): 1287-1289. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al: Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003, 13 (11): 2498-2504. Ideker T, Ozier O, Schwikowski B, Siegel AF: Discovering regulatory and signalling circuits in molecular interaction networks. Bioinformatics. 2002, S233-S240. 18 Suppl 1 Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, et al: Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet. 2000, 25 (1): 25-29. Kamburov A, Stelzl U, Lehrach H, Herwig R: The ConsensusPathDB interaction database: 2013 update. Nucleic Acids Res. 2013, 41 (Database issue): D793-D800. Huang da W, Sherman BT, Lempicki RA: Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009, 4 (1): 44-57. Fulton DL, Sundararajan S, Badis G, Hughes TR, Wasserman WW, Roach JC, et al: TFCat: the curated catalog of mouse and human transcription factors. Genome Biol. 2009, 10 (3): R29- Lanzetti L, Di Fiore PP: Endocytosis and cancer: an 'insider' network with dangerous liaisons. Traffic. 2008, 9 (12): 2011-2021. Rzeski W, Ikonomidou C, Turski L: Glutamate antagonists limit tumor growth. Biochem Pharmacol. 2002, 64 (8): 1195-1200. Conticello C, Adamo L, Giuffrida R, Vicari L, Zeuner A, Eramo A, et al: Proteasome inhibitors synergize with tumor necrosis factor-related apoptosis-induced ligand to induce anaplastic thyroid carcinoma cell death. J Clin Endocrinol Metab. 2007, 92 (5): 1938-1942. Shulman GI, Ladenson PW, Wolfe MH, Ridgway EC, Wolfe RR: Substrate cycling between gluconeogenesis and glycolysis in euthyroid, hypothyroid, and hyperthyroid man. J Clin Invest. 1985, 76 (2): 757-764. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell. 2000, 100 (1): 57-70. Ozcan A, Shen SS, Hamilton C, Anjana K, Coffrey D, Krishnan B, et al: PAX 8 expression in non-neoplastic tissues, primary tumors, and metastatic tumors: a comprehensive immunohistochemical study. Mod Pathol. 2011, 24 (6): 751-764. Saharinen P, Tammela T, Karkkainen MJ, Alitalo K: Lymphatic vasculature: development, molecular regulation and role in tumor metastasis and inflammation. Trends Immunol. 2004, 25 (7): 387-395. Klein I, Ojamaa K: Thyroid hormone and the cardiovascular system. N Engl J Med. 2001, 344 (7): 501-509. Yang J, Weinberg RA: Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell. 2008, 14 (6): 818-829. Dvorak HF: Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol. 2002, 20 (21): 4368-4680. Vivanco I, Sawyers CL: The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer. 2002, 2 (7): 489-501. Kouvaraki MA, Shapiro SE, Perrier ND, Cote GJ, Gagel RF, Hoff AO, et al: RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors. Thyroid. 2005, 15 (6): 531-544. Darnell JE: Transcription factors as targets for cancer therapy. Nat Rev Cancer. 2002, 2 (10): 740-749. Krueger KE, Srivastava S: Posttranslational protein modifications: current implications for cancer detection, prevention, and therapeutics. Mol Cell Proteomics. 2006, 5 (10): 1799-1810.